Seagen Inc. - SGEN STOCK NEWS

Seagen Inc. (Nasdaq: SGEN) will participate in a virtual fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, 2021, at 2:00 PM Eastern Time. The presentation will be available via live webcast and can be replayed later on Seagen's official website. Seagen is a global biotechnology company focused on developing transformative cancer medicines, headquartered in the Seattle area, with operations in California, Canada, Switzerland, and the European Union.

Seagen Inc. announced data from ongoing trials will be presented at the ESMO 2021 Annual Meeting, highlighting the safety and efficacy of tisotumab vedotin in treating recurrent or metastatic cervical cancer. Key presentations include interim analyses of tisotumab vedotin combined with chemotherapy. The FDA is currently reviewing Seagen’s Biologics License Application for tisotumab vedotin, with a target action date of October 10, 2021. The company remains committed to transforming cancer treatment through innovative therapies.

Seagen Inc. (Nasdaq: SGEN) and RemeGen Co., Ltd. have entered an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate (ADC). Seagen will provide a $200 million upfront payment and up to $2.4 billion in milestone payments. Disitamab vedotin has shown promising antitumor activity in clinical trials for multiple cancers and has received FDA Breakthrough Therapy designation. This collaboration enhances Seagen's position in the ADC market and aims to expand access to innovative cancer therapies globally.

Seagen Inc. (Nasdaq: SGEN) reported strong financial results for Q2 2021, with total revenues reaching $388.5 million and $720.5 million for the first six months, a growth of 39.9% and 40.6% respectively compared to 2020. The substantial rise was primarily driven by record net product sales of its oncology drugs, notably TUKYSA, which saw a remarkable 427% increase. However, the company reported a net loss of $84.6 million for Q2. Seagen is also anticipating a fourth product, tisotumab vedotin, with an FDA action date in October 2021.

Seagen and Astellas announced the FDA's regular approval of PADCEV for adult patients with locally advanced or metastatic urothelial cancer ineligible for cisplatin-based chemotherapy. This therapy, previously granted accelerated approval in 2019, shows a median overall survival of 12.9 months with PADCEV versus 9.0 months with chemotherapy, based on the EV-301 trial. The approval addresses a critical need for treatment options in this patient group, which often has poor prognoses.

Astellas Pharma and Seagen announced that the FDA granted regular approval for PADCEV® (enfortumab vedotin-ejfv) for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin chemotherapy. This approval follows its accelerated approval in 2019 and is based on data from the Phase 3 EV-301 trial, which demonstrated a median overall survival of 12.9 months for PADCEV versus 9.0 months for chemotherapy. The drug offers an important treatment option for patients with limited therapies and poor prognosis.

Seagen Inc. (Nasdaq: SGEN) will announce its second quarter 2021 financial results on July 29, 2021, after U.S. markets close. Management will hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and provide a business update. Interested participants can join via telephone or access the webcast on the company’s website. Seagen focuses on developing transformative cancer medicines and is headquartered in the Seattle area, with additional offices in California, Canada, Switzerland, and the EU.

Seagen Inc. (Nasdaq: SGEN) reported sustained improvements in overall survival (OS) and progression-free survival (PFS) in the HER2CLIMB trial, evaluating TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine for HER2-positive metastatic breast cancer. The median OS was 24.7 months for the TUKYSA regimen versus 19.2 months for the control arm, with a significant hazard ratio of 0.73. PFS also improved to 7.6 months compared to 4.9 months. Safety profiles were consistent with prior analyses, showing manageable adverse events.

Seagen (Nasdaq: SGEN) will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 2:10 p.m. ET. The event will be webcast live, with a replay available on Seagen's website in the Investors section. Seagen is dedicated to transforming cancer treatment through innovative medicines and is headquartered near Seattle, with additional locations in California, Canada, Switzerland, and the EU. For detailed information on Seagen’s products and pipeline, visit www.seagen.com.